Braidy N; Bui K; Bajorek Beata
(Centro de Investigaciones y Publicaciones Farmaceuticas, 2011)
ABSTRACT* The short-comings of current anticoagulants have led to the development of newer, albeit more expensive, oral alternatives. Objective: To explore the potential impact the new anticoagulants dabigatran and rivaroxaban ...